Gossamer Bio, Inc.
Financials
Valuation Metrics
Gossamer Bio, Inc.'s Market Cap is $5.25B. At end of 2025 it was $702M. Ranked #1246 of 3,121 in US market (top 40%), #417 of 1,463 on NASDAQ (top 29%), #71 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.25B | US#1,246/3,121 Sec#71/266 |
| Revenue | $53M | US#2,770/3,121 Sec#149/266 |
| Net Income | $-125M | US—/3,121 Sec—/266 |
| Total Assets | $77M | US#3,073/3,121 Sec#264/266 |
| Net Assets | $-94M | US#2,966/3,121 Sec#252/266 |
| Employees | 162 | US#2,532/3,121 Sec#140/266 |
| Value | ||
| P/S | 98.44x | US#2,951/3,121 Sec#180/266 |
| FCF Yield | -3.10% | US—/3,121 Sec—/266 |
| Profitability | ||
| Op. Margin | -311.70% | US#2,790/3,121 Sec#145/266 |
| Revenue Growth | 32.43% | US#391/3,121 Sec#61/266 |
| Financial Health | ||
| Total Debt | $39M | US#2,653/3,121 Sec#164/266 |
| FCF | $-163M | US#2,739/3,121 Sec#189/266 |
| Cash | $41M | US#2,659/3,121 Sec#238/266 |
| Current Ratio | 0.53x | US#2,702/3,121 Sec#268/266 |
| Performance | ||
| 1Y Return | 248.38% | US#29/3,121 Sec#14/266 |
| 1M Return | 6751.85% | US#1/3,121 Sec#1/266 |
| From 52W High | -27.25% | US#1,445/3,121 Sec#105/266 |
| 1Y MDD | -96.41% | US#3,127/3,121 Sec#268/266 |
| Trading | ||
| Volume | 473,917 shares | US#2,486/3,121 Sec#240/266 |
| Trading Value | $5M | US#2,796/3,121 Sec#239/266 |
| Per Share | ||
| EPS | $-0.26 | US—/3,121 Sec—/266 |
| BPS | $-0.19 | US—/3,121 Sec—/266 |
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.